Back to Search Start Over

COVID-19 Vaccine Effectiveness against Omicron Variant among Underage Subjects: The Veneto Region’s Experience

Authors :
Silvia Cocchio
Federico Zabeo
Giulia Tremolada
Giacomo Facchin
Giovanni Venturato
Thomas Marcon
Mario Saia
Michele Tonon
Michele Mongillo
Filippo Da Re
Francesca Russo
Vincenzo Baldo
Source :
Vaccines, Vol 10, Iss 8, p 1362 (2022)
Publication Year :
2022
Publisher :
MDPI AG, 2022.

Abstract

Even if most of the complications due to COVID-19 are observed in the elderly, in Italy the impact of COVID-19 among young people has not been negligible. Furthermore, their contribution to SARS-CoV-2 circulation is still unclear. These reasons have driven policy makers to involve subjects aged 5 to 17 years in the COVID-19 vaccination campaign. However, the trade-off of vaccinating this age-group should be further investigated, especially in view of the rise of new immunologically evasive variants of concern (VOCs). We used regional databases to retrospectively estimate vaccine effectiveness over time of each approved vaccination schedule among children (5–11) and adolescents (12–17). Our findings suggest that COVID-19 vaccines were highly effective and their protection levels lasted longer during a period of Delta variant predominance, whereas they offered just mild to moderate levels of protection—apparently affected by a rapid waning effect—in a period of Omicron variant predominance. Considering these results, it is plausible to evaluate a reformulation of possible future COVID-19 vaccination campaigns among underage subjects. However, effectiveness against serious complications due to COVID-19, as well as indirect benefits of underage vaccinations, should first be addressed. Furthermore, vaccine effectiveness should be kept monitored, as new VOCs may arise, but also new adapted vaccines may start being administered.

Details

Language :
English
ISSN :
2076393X
Volume :
10
Issue :
8
Database :
Directory of Open Access Journals
Journal :
Vaccines
Publication Type :
Academic Journal
Accession number :
edsdoj.4a5bbd095d364715ac6cdf935a3abd05
Document Type :
article
Full Text :
https://doi.org/10.3390/vaccines10081362